Simplicity Of Working Memory Study Could Help With ADD And Other Attention Difficulties
A mind is a terrible thing to waste, but humans may have even less to work with than previously thought. University of Missouri researchers found that the average person can keep just three or four things in their "working memory" or conscious mind at one time.
OROS R Methylphenidate In Adults With ADHD: New Insights
Although once considered to be a disorder only seen in children, Attention Deficit Hyperactivity Disorder (ADHD) is now known to be a condition associated with a wide range of functional impairments throughout the lifespan(1). In the US, the overall prevalence of ADHD in adults is estimated to range between 3.
New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA TM methylphenidate Transdermal System , Offered ADHD Symptom Control For 12 Months
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA(TM) (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
Shire Investigational Nonstimulant INTUNIV Showed Significant Efficacy In Reducing ADHD Symptoms
Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
New European Study Showed OROS R Methylphenidate Tablets Significantly Improved Symptoms In Adults With ADHD
Adults with attention deficit hyperactivity disorder (ADHD) treated in an investigational study with OROS methylphenidate tablets experienced significantly greater improvements in their ADHD symptoms compared to patients taking placebo, according to findings from a trial published in Biological Psychiatry.
Researcher Reports On Noninvasive Device For GERD, Obesity
A new, noninvasive gastroplasty device to treat two separate disorders gastroesophageal-reflux disease (GERD) and morbid obesity was reported by its inventor, Charles J. Filipi, M.D., professor of surgery at Creighton University School of Medicine.
ADHD Stimulant Treatment Has No Effect On Risk Of Future Substance Abuse
A new study finds that the use of stimulant drugs to treat children with ADHD has no effect on their future risk of substance abuse. The report, which will appear in the American Journal of Psychiatry and has been issued online, assessed more than 100 young men 10 years after they had been diagnosed with ADHD and is the most methologically rigorous analysis of any potential relationship between stimulant treatment and drug abuse.
For Boys With Fragile X Sydrome And ADHD, New Hope Found In Non-Stimulant Medication
The most common hereditary form of hereditary mental retardation isknown as Fragile X syndrome (FXS), so dubbed for its characteristicmutation on the X chromosome, or Escalante's syndrome. Manifestationsof this disease in patients usually include a characteristic longfacial pattern, tooth and jaw misalignment, musculoskeletalabnormalities, or autism.
Methylphenidate Can Have Sleep Benefits In Adults With ADHD
Treatment with methylphenidate (MPH) appears to have beneficial effects on sleep parameters in adults with ADHD, including increased sleep efficiency and a feeling of improved restorative value of sleep, according to a study published in the March 1 issue of the journal SLEEP.
Auriga Laboratories Announces FDA Approval Of Liquadd TM Oral Solution For The Treatment Of ADHD And Upcoming Product Launch
Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced today the FDA approval of Liquadd™ (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL indicated for the treatment of Attention Deficit Disorder with Hyperactivity (ADHD).